Achieving the goal of malaria elimination will depend on targeting Plasmodium pathways essential across all life stages. Here we identify a lipid kinase, phosphatidylinositol-4-OH kinase (PI(4)K), as the target of imidazopyrazines, a new antimalarial compound class that inhibits the intracellular development of multiple Plasmodium species at each stage of infection in the vertebrate host. Imidazopyrazines demonstrate potent preventive, therapeutic, and transmission-blocking activity in rodent malaria models, are active against blood-stage field isolates of the major human pathogens P. falciparum and P. vivax, and inhibit liver-stage hypnozoites in the simian parasite P. cynomolgi. We show that imidazopyrazines exert their effect through inhibitory interaction with the ATP-binding pocket of PI(4)K, altering the intracellular distribution of phosphatidylinositol-4-phosphate. Collectively, our data define PI(4)K as a key Plasmodium vulnerability, opening up new avenues of target-based discovery to identify drugs with an ideal activity profile for the prevention, treatment and elimination of malaria.
To eliminate malaria, broadly acting medicines must be developed that cure the symptomatic asexual blood stage, clear the preceding liverstage infection that can cause relapses and block parasite transmission to mosquitoes 1 . Relapse prevention is especially important for P. vivax, which forms intra-hepatic hypnozoites that can persist for years before reinitiating development and triggering blood-stage infection. Primaquine is the only licensed antimalarial capable of eliminating the hypnozoite reservoir and delivering a radical cure. However, side effects and weak activity against blood stages preclude widespread use of primaquine 2 . Because the target of primaquine and mechanism of action are not known, the search for radical cure drugs has been limited to related analogues, such as tafenoquine 3 . There is a clear need for druggable and chemically validated targets that are essential in all life-cycle stages of the malaria parasite.
Here we report that a parasite PI(4)K type III beta (PI(4)KIIIb), a ubiquitous eukaryotic enzyme that phosphorylates lipids to regulate intracellular signalling and trafficking, is inhibited by imidazopyrazines. In blood stages, imidazopyrazines block a late step in parasite development by disrupting plasma membrane ingression around developing daughter merozoites. This probably stems from altered phosphatidylinositol-4phosphate (PI(4)P) pools and disrupted Rab11A-mediated membrane trafficking. To our knowledge, these findings are the first validation of a drug target that is required across all Plasmodium life-cycle stages.
Imidazopyrazines target several life stages
A cell-based screen against P. falciparum asexual blood-stage parasites 4 revealed a new class of antimalarials with an imidazopyrazine core ( Fig. 1a ). This compound was distinct from known antimalarials and was active against several drug-resistant strains (half-maximum inhibitory concentration (IC 50 ) 27-70 nM; Extended Data Table 1 and Extended Data Fig. 1a ), suggesting a new mechanism of action. Synthetic derivatives with potency and pharmacokinetic properties suitable for testing in animal models were designed and showed activity in vivo (data shown for KDU691; Extended Data Table 2 and Extended Data Fig. 1b ).
We evaluated imidazopyrazines ( Fig. 1a ) against all parasite life-cycle stages in the vertebrate host. First, a cell-based assay showed potent inhibition of liver-stage development of the rodent parasite, P. yoelii, with IC 50 values less than 160 nM and as low as 9 nM (Fig. 1b) for KDU691, KAI407 and KAI715. In vivo, KDU691 administered orally at the time of infection prophylactically protected mice from colonization with transgenic P. berghei sporozoites expressing luciferase. Just a single dose (7.5 mg kg 21 ; Fig. 1c and Extended Data Fig. 1c ) prevented what would normally be a fatal outcome. To determine whether KDU691 could eliminate an existing infection, animals were dosed 24, 36 or 48 h after sporozoite inoculation, well after the onset of liver-stage development (which lasts 48 h in P. berghei). This delayed treatment rapidly eliminated the luciferase-expressing parasites with a single dose ( Fig. 1c ). KDU691 was also active at low concentrations (IC 50 , 196 nM; Fig. 1d ) against in vitro cultured liver-resident hypnozoites of the simian parasite P. cynomolgi 5 . Collectively, these data demonstrate that KDU691 is active against liver stages in several Plasmodium species, including hypnozoites associated with malaria relapse. To assess imidazopyrazine activity against a human parasite that forms hypnozoites, we tested blood-stage P. vivax field isolates for sensitivity. KDU691 potency against P. vivax (mean IC 50 , 69 nM) was comparable to that observed in parallel studies conducted with field isolates of the more prevalent human pathogen P. falciparum (mean IC 50 , 118 nM; Fig. 1e ).
A small proportion of asexual blood-stage parasites sexually differentiate into gametocytes that transmit to the mosquito vector. Gametocytes are often not killed by drugs that provide symptomatic relief 6 . We sought to determine the transmission-blocking potential by assessing compound activity on gametocyte viability and the mosquito-specific stages of gamete and oocyst formation. An enriched gametocyte population was treated with either KDU691 or dihydroartemisinin (DHA), a licensed antimalarial with gametocytocidal activity 7 . Both compounds reduced gametocyte viability in a dose-dependent manner, with KDU691 displaying an IC 50 value of 220 nM (Extended Data Fig. 1d ). Furthermore, 200 nM KDU691 reduced gamete formation by 60%, comparable to that achieved with 1 mM DHA (Fig. 1f ). Lastly, we tested compounds in the 'standard membrane feeding assay' that directly monitors transmission to the mosquito 8 . Transmission was completely inhibited at 1 mM KDU691 (Fig. 1g) , with dose-dependent suppression of oocyst densities (IC 50 , 316 nM; Extended Data Fig. 1e ) and oocyst prevalence (that is, the number of infected mosquitoes; IC 50 , 370 nM; Extended Data Fig. 1f ). Altogether, these data indicate that KDU691 is effective at blocking transmission, and suggest it targets a conserved function throughout the Plasmodium life cycle.
Inhibition of blood-stage cytokinesis
Imidazopyrazine-treated parasites accumulated multinucleated schizonts ( Fig. 2a) , leading us to test compound effects when administered at distinct stages during development in red blood cells (RBCs). Parasite reinvasion was markedly inhibited even when KAI407 was added late in the intraerythrocytic cycle, up to 44 h after invasion ( Fig. 2b) . Conversely, early ring-stage parasites exposed continuously to KAI407 for up to 40 h followed by drug washout demonstrated no appreciable loss of parasite viability (Extended Data Fig. 2a ). These data indicate that the imidazopyrazine target is most critical at a very late stage in the 48 h intraerythrocytic cycle.
We next tested whether drug-treated parasites arrest during maturation of daughter merozoites or form daughter cells that fail to egress from the host cell 9, 10 . Synchronized imidazopyrazine-treated parasites were mechanically ruptured, yielding a reinvasion parasitaemia near 0.01% ( Fig. 2c ), suggesting a defect in merozoite formation. As a control, merozoites that were artificially retained within a mature parasite by treatment with E-64, a protease inhibitor that blocks egress 11 , and then mechanically released remained viable and capable of reinfecting RBCs, yielding 2-3% parasitaemia 9,10 ( Fig. 2c ). Mock-treated parasites that had been allowed to reinvade naturally yielded a parasitaemia of 8-10%.
To visualize drug-induced cellular defects, we examined a transgenic line expressing green fluorescent protein (GFP)-tagged PfATP4, a plasma-membrane protein 12 that reveals merozoite envelopment during biogenesis. Control E-64-treated parasites showed complete plasma membrane ingression around each daughter cell ( Fig. 2d and Extended Data Fig. 2b ). By contrast, KAI407-treated parasites showed incomplete and disorganized segmentation, lacking merozoites that were fully enclosed by membranes with PfATP4-GFP, suggesting perturbation of plasma membrane ingression ( Fig. 2d and Extended Data Fig. 2c ). On the basis of the timing of growth inhibition and the observed cellular phenotype, we conclude that imidazopyrazines impair cytokinesis by interfering with membrane biogenesis around the developing merozoite.
Plasmodium PI(4)K target identification
To determine the mechanism of broad antimalarial activity by imidazopyrazines, we next sought to elucidate their target using forward genetics. We selected imidazopyrazine-resistant blood-stage P. falciparum 
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parasites in vitro using either KAI407 or KAI715. Resistant lines were evolved in three independent flasks for each compound, with several clones isolated from each flask for IC 50 characterization ( Fig. 3a ). For each clone, we identified genomic differences relative to the parent using a genome-tiling microarray 13 . All five KAI407-resistant clones shared alterations to a single gene, pfpi4k (PlasmoDB accession PF3D7_0509800; PI(4)KIIIb), one of two annotated PI(4)Ks. Type IIIb phosphatidylinositide kinases (Extended Data Fig. 3a , b) are conserved among eukaryotes and function to convert phosphatidylinositol to PI(4)P. Within the cell, PI(4)P regulates effector protein recruitment and lipid-sorting events at the Golgi, and is a precursor for the generation of phosphatidylinositol-4,5-bisphosphate at the plasma membrane 14, 15 . Three KAI407-resistant clones possessed copy number variations (CNVs) that included pfpi4k (Extended Data Fig. 4a ). In the remaining two clones, a single nucleotide variant (SNV) was detected in the second exon of pfpi4k (Extended Data Fig. 4b ). Sequencing of pfpi4k in these two independently evolved clones revealed an identical nonsynonymous SNV that led to a His1484Tyr coding change. Removal of drug pressure for 3 months resulted in resensitization of one clone (KAI407-R3-REV) to KAI407, with a corresponding reversion in pfpi4k to the wild-type sequence, supporting a role for this variant in KAI407 resistance ( Fig. 3a ). Selections with KAI715 yielded two resistant clones, one of which (KAI715-R4) also implicated pfpi4k amplification in resistance (Extended Data Fig. 4c ). The second clone (KAI715-R5) possessed a solitary Asp139Tyr mutation in a second gene product, the small GTPase PfRab11A (PF3D7_1320600) (Extended Data Fig. 4d ). Notably, PI(4)K binds and regulates Rab11A in Drosophila spermatocytes 16 , consistent with a related function in membrane trafficking.
Our imidazopyrazine-resistant lines provide compelling evidence for PI(4)KIIIb as the plasmodial drug target. Orthologues of PI(4)KIIIb are found in all Plasmodium species and are extensively conserved at the amino acid level, including 97% identity in the catalytic domain between the P. falciparum and P. vivax orthologues (Extended Data Fig. 3b ). Conservation with the catalytic region of human PI(4)KIIIb is less significant, with only 43% identity. The partial sequence conservation between the human and Plasmodium orthologues of PI(4)KIIIb (Extended Data Fig. 3b ) led us to test whether some inhibitors of the human kinase might also exert antimalarial activity.
Subsequent screening of a Novartis compound library led us to identify BQR695 (Fig. 1a ), a quinoxaline that displayed sub-micromolar potency against both human PI(4)KIIIb (IC 50 , 90 nM; Extended Data Table 3 ) and P. falciparum asexual blood stages (IC 50 , 71 nM). BQR695, which showed no evidence of toxicity against mature RBCs, induced a schizont-stage arrest indistinguishable from that observed in imidazopyrazine-treated parasites (Extended Data Fig. 2d , e), and exhibited cross-resistance with the imidazopyrazine-resistant lines (Fig. 3a) . These data confirm a shared mechanism of action and of resistance with the imidazopyrazines. To test this association further, we evolved BQR695-resistant parasites. Whole-genome scanning of three independently selected lines (BQR695-R) showed two instances of CNVs involving pfpi4k (Extended Data Fig. 4e ), and a new mutation (Ser1320Leu) in pfpi4k (Extended Data Fig. 4f ). Sequencing of pfpi4k in the CNVcontaining lines revealed that BQR695-R7 had at least one pfpi4k copy with a Tyr1356Phe coding change, which was associated with a higher degree of resistance to BQR695 ( Fig. 3a ). All three resistance-associated SNVs, Ser1320Leu, Tyr1356Phe and His1484Tyr, mapped to the catalytic domain of PfPI(4)K (Extended Data Fig. 3a, b) . Notably, the three imidazopyrazines (KAI407, KAI715 and KDU691) and the quinoxaline BQR695 demonstrated comparable cross-resistance against all drug-resistant lines ( Fig. 3a ). Collectively, these data provide compelling chemical and genetic evidence that PI(4)K is the direct drug target of imidazopyrazine and quinoxaline compounds.
PI(4)K variation confers drug resistance
To confirm the role of pfpi4k and pfrab11a mutations in resistance, we engineered these variants into drug-sensitive parasites. We generated recombinant parasites bearing individual pfpi4k SNVs using zinc-finger nuclease (ZFN) technology 17 . Genome editing was confirmed by direct sequencing (Fig. 3b ) and whole-genome analysis (.203 coverage across 96.4% of the genome; Extended Data Table 4 ). Genome-edited Dd2 parasites containing either the Ser1320Leu or His1484Tyr mutations were resistant to both imidazopyrazine and quinoxaline compounds ( Fig. 3c and Extended Data Fig. 5a ) and yielded resistance comparable to the original drug-evolved lines. By contrast, the Tyr1356Phe mutation conferred resistance specifically to the quinoxaline BQR695 but not to the imidazopyrazines (Fig. 3c ). In comparison, the evolved line BQR695-R7, which possessed both the Tyr1356Phe mutation as well as a CNV, showed resistance to both imidazopyrazine and quinoxaline compounds ( Fig. 3a) .
Because several resistant lines contained CNV events, we sought to determine whether increased copy numbers of wild-type PI(4)K could alone mediate protection. We generated a stable parasite line overexpressing GFP-tagged PI(4)K (ref. 18 ). GFP-PI(4)K was diffusely localized in trophozoite-stage parasites and enriched at the apical ends of developing daughter merozoites (Extended Data Fig. 3c ). Expression of this additional wild-type copy of PfPI(4)K resulted in decreased susceptibility to both imidazopyrazine and quinoxaline compounds, confirming that CNVs can contribute to resistance and providing evidence that the GFP-tagged protein is functional ( Fig. 3d ). Collectively, these data demonstrate that PfPI(4)K can mediate resistance to the imidazopyrazines in asexual blood stages through either increased copy number or point mutations.
We next investigated whether PI(4)K variants could confer resistance in liver-stage parasites. Introduction of a mutation analogous to 
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His1484Tyr into P. berghei (His1477Tyr) conferred a significant IC 50 shift for the imidazopyrazine and quinoxaline compounds against in vitro liver-stage parasites ( Fig. 3e ). Importantly, these data show that the mechanism of action for these inhibitors is conserved between life-cycle stages. We next tested the validity of the Rab11A(Asp139Tyr) variation, which conferred a modest, but significant, resistance phenotype (KAI715-R5; Fig. 3a ). The Asp139Tyr SNV lies on the a4 helix of Rab11A, distant from the GTP-binding site (Extended Data Fig. 6a, b ). GFP-tagged versions of both wild-type and Rab11A(Asp139Tyr) showed a predominantly cytosolic localization that became apically punctate in late schizonts (Extended Data Fig. 6c, d ), consistent with a previous report 19 . As expected, the Asp139Tyr mutant conferred modest resistance against KAI407 ( Fig. 3d ).
If PI(4)K is the cellular target of the imidazopyrazines, then its function should be essential in most stages of the Plasmodium life cycle. We therefore tested the essentiality of pfpi4k in the asexual blood stages by using ZFNs to introduce a stop codon at position Tyr 1356, which lies within the catalytic site of the kinase domain (see Fig. 4a , b). This Tyr 1356 stop-editing experiment was attempted in three independent transfections. Unlike the Tyr1356Phe mutation, which was readily isolated in ,18% of clones, two transfection reactions produced 0 out of 35 clones with a stop codon. From a third transfection, one clone yielded a duplication on chromosome 5 that partially encompassed pfpi4k and placed the edited stop codon within a truncated copy of the gene (Extended Data Fig. 5b , c). These data strongly indicate that gene editing could not be achieved without a duplication event that preserved one copy of the gene, confirming pfpi4k essentiality to blood-stage growth.
Biochemical validation of PfPI(4)K
We performed in silico modelling on a PfPI(4)K homology model based on related phosphatidylinositol-3-OH kinases (Fig. 4a ), finding that both KAI407 and BQR695 were accommodated in the ATP-binding pocket. The nitrogen at position 1 of the imidazole ring of KAI407 is predicted to make a crucial hydrogen bond contact with the main-chain amide from Val 1357 that lies adjacent to the Tyr1356Phe mutation ( Fig. 4b ). This 'hinge-binding' contact is common among protein kinase inhibitors, and mimics the hydrogen bonds made by the adenine of ATP 20 .
To confirm that imidazopyrazines directly inhibit PI(4)K function, we expressed full-length recombinant P. vivax PI(4)K (PvPI(4)K). KDU691 and BQR695 showed dose-dependent inhibition of PvPI(4)K activity ( Fig. 4c, d) , with IC 50 values of 1.5 and 3.5 nM, respectively, in the presence of 10 mM ATP. Furthermore, compound potency decreased with increasing concentrations of ATP, indicative of ATP-competitive inhibition, providing further evidence that imidazopyrazines and quinoxalines bind to the ATP-binding pocket of parasite PI(4)K. Mutations homologous to the PfPI(4)K resistance-conferring variants (Extended Data Fig. 3b ) generated resistance profiles ( Fig. 4e ) similar to those observed with the respective drug-resistant parasite lines (Fig. 3a, c) . In contrast to the low nanomolar activity observed against parasite PI(4)K, KDU691 and KAI407 did not significantly inhibit any of the .40 enzymes in a panel of human kinases, and both were at least 1,000 times more potent against the parasite enzyme than against any human lipid kinase (Extended Data Table 3 ), demonstrating remarkable selectivity. This specificity precludes the possibility that imidazopyrazine antimalarial activity derives from the inhibition of host kinases.
Perturbed cellular distribution of PI(4)P
Finally, we examined the consequences of PfPI(4)K inhibition on intracellular PI(4)P. Unexpectedly, high-performance liquid chromatography (HPLC) analysis of radiolabelled phospholipids did not reveal a decrease in total PI(4)P after imidazopyrazine treatment (Extended Data Fig. 3d ).
To determine whether imidazopyrazines might instead change the intracellular distribution of PI(4)P, we generated a transgenic parasite expressing a validated PI(4)P-specific probe, GFP-PH Osh2 , which consists of GFP fused to two tandem PI(4)P-binding pleckstrin homology (PH) domains from yeast Osh2 (ref. 21) (Fig. 4f ). In yeast, this marker defines two populations of PI(4)P-one at the plasma membrane, and one intracellular population, with the latter diminished by inhibition of the Golgi-localized PI(4)K homologue Pik1 (ref. 21) . Similarly, in P falciparum, GFP-PH Osh2 localized to intracellular foci, and, to a lesser degree, the parasite plasma ARTICLE RESEARCH membrane (Fig. 4g ). Treatment with 0.5 mM of either KAI407 or BQR695 caused GFP-PH Osh2 to redistribute to the parasite plasma membrane (Fig. 4g, h) , consistent with depletion of intracellular PI(4)P after inhibition of PfPI(4)K function.
Discussion
Here we report the identification of PI(4)K as an essential and druggable target of imidazopyrazine and quinoxaline compounds that block development at multiple stages of the Plasmodium life cycle, implicating this phosphatidylinositol kinase as a crucial cellular regulatory molecule. PfPI(4)K functionally complements yeast Pik1, an essential Golgi-localized PI(4)KIIIb (ref. 22) . Our data indicate that, like Pik1 (refs 23-25), PfPI(4)K regulates essential membrane trafficking events, with the plasmodial protein required for the late-stage membrane ingression that drives completion of the asexual erythrocytic stages. We propose that Plasmodium PI(4)K acts at the Golgi to locally generate PI(4)P, which in turn recruits effectors that generate transport vesicles destined for the ingressing plasma membrane (Fig. 5 ). One obvious candidate effector is Rab11A, which has also been linked to PI(4)K in Drosophila and mammalian cells 16, 26 . Drosophila PI(4)K and Rab11 act during cytokinesis, regulating membrane delivery to complete cell division 16 , which mirrors our findings of failed membrane ingression after PfPI(4)K inhibition. Rab11A may bind directly to PI(4)K and/or PI(4)P, or may instead be recruited indirectly by an intermediate protein.
In either case, Rab11A probably marks these Golgi-derived vesicles to modulate delivery to the target compartment, a role consistent with previous findings implicating Plasmodium Rab11A in cytokinesis 19 .
Our results provide genetic, chemical and biochemical validation of Plasmodium PI(4)K as a target suitable for antimalarial drug discovery. Although the imidazopyrazine compounds described here may serve primarily as tool compounds, further optimization could lead to clinical candidates with desirable drug-like characteristics. Maintaining their remarkable selectivity for Plasmodium PI(4)K will be an important feature for an ultimate antimalarial drug because chronic PI(4)KIIIb inhibition in humans causes immunosuppressive effects 27 that could preclude long-term malaria prophylaxis. Because the emergence of resistant parasites has diminished the effectiveness of all licensed antimalarial therapies, most of which were introduced as monotherapies, clinical candidates will necessarily require combination with mechanistically distinct drug partner(s) to mitigate the potential for drug resistance and to complement the PI(4)K inhibitors' narrow and late stage of action in the asexual blood stage.
Collectively, our data identify Plasmodium PI(4)K as a new drug target that operates in all life-cycle stages of the parasite, and is therefore suitable for the development of next-generation antimalarial drugs capable of curing, preventing and blocking the transmission of the disease. We anticipate that our findings will rapidly yield clinical candidates compatible with single exposure, radical cure and prophylaxis, a profile widely heralded as crucial for the success of worldwide malaria elimination efforts 28 .
METHODS SUMMARY
Imidazopyrazine and quinoxaline activity were demonstrated throughout the vertebrate life cycle, with eight specific assays detailed in the Methods: in vitro highcontent imaging assay against P. yoelii 29 and P. cynomolgi exo-erythrocytic forms; in vivo causal prophylaxis mouse model, in which parasitaemia was monitored by in vivo imaging of the luciferase-expressing P. berghei line 29 ; in vitro asexual-stage KAI407 BQR695 H1484 S1320 S1320 V1357 90 °2 Model depicting daughter merozoite biogenesis in a late-stage schizont, showing plasma membrane (PM) ingression and development of the underlying inner membrane complex (IMC). Delivery of post-Golgi secretory vesicles to the invaginating plasma membrane requires PfPI(4)K-driven production of PI(4)P, which probably recruits lipid-binding effector proteins in a Rab11Adependent process. N, nucleus; PVM, parasitophorous vacuolar membrane.
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activity against P. falciparum, measured using a modified SYBR Green cell proliferation assay 4 ; ex vivo asexual-stage assay against P. vivax and P. falciparum isolates collected from Thailand 30, 31 ; gametocyte viability assays against P. falciparum NF54 stage III2V gametocytes measured by a modified Plasmodium lactate dehydrogenase assay 32 ; in vitro gametogenesis assay against P. falciparum quantified by flow cytometry 33 ; and P. falciparum transmission to Anopheles stephensi mosquitoes in a standard membrane feeding assay 34 . Stage of action studies 12 and a merozoite release assay 9,10 were used to identify specific arrest of drug-treated asexual parasites in mid-schizogony. An established protocol 13 was used for in vitro evolution and comparative genomic analysis of KAI407-, KAI715-or BQR695-resistant lines. Resistance-conferring mutations were validated with ZFN approaches 17 and standard transfection-based methods 12 . Genomic DNA libraries generated on an Illumina HiSeq 2000 were analysed with PlaTypUS, an internal WGS pipeline. A P. berghei line expressing PI(4)K(His1477Tyr) was generated by standard methods 35 , and resistance was quantified against liver-stage parasites 29 . A homology model of PfPI(4)K was built from atomic coordinates for human phosphatidylinositol-3-OH kinase gamma (PI(3)Kc; Protein Data Bank accession 3ENE) and used for flexible ligand docking studies within Glide (Schrödinger). Full-length PvPI(4)K was expressed in a SF9/ baculovirus system and assayed for drug inhibition with the Transcreener ADP 2 FP detection kit (BellBrook). PI(4)P pools were detected in asexual stage parasites by expression of tandem Osh2 pleckstrin homology domains fused to GFP 21 . 
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METHODS
Statistical analysis. Data are shown as mean 6 s.d., and represent at least two independent experiments performed in duplicate unless stated otherwise. Statistical significance between groups was determined using an unpaired, nonparametric analysis via the Mann-Whitney U test (with GraphPad Prism Software). The Mann-Whitney test does not require the assumption that the differences between the two samples are normally distributed. P values were considered significant if P , 0.05. P. berghei and P. yoelii sporozoite generation. The New York University Insectary provided A. stephensi mosquitoes infected with rodent malaria: Plasmodium yoelii (17XNL), a transgenic P. berghei expressing luciferase (ANKA) or an engineered P. berghei ANKA line with H1477Y-PbPI(4)K (see below). Plasmodiuminfected mosquitoes were dissected 22-25 days after an infective blood meal, and sporozoites purified as described previously 29 . P. yoelii liver schizont assay. A previously described 29 , in vitro high-content imaging assay was used to measure the proliferation of P. yoelii sporozoites after invasion of a transgenic hepatoma line (HepG2-A16-CD81-EGFP; obtained from the laboratory of D. Mazier; tested monthly for mycoplasma contamination; used for up to 50 passages). Anti-PyHSP70-stained exoerythrocytic forms were quantified using the Opera Confocal High Content Screening System (PerkinElmer). Atovaquone and DMSO-treated wells were used as controls on each assay plate. IC 50 values were obtained using mean parasite area and a custom curve fitting model, and a standard logistic regression model was applied for curve fitting.
In vivo pharmacokinetic studies and causal prophylaxis efficacy. All animalrelated procedures at GNF were non-blinded and conducted under an IACUCapproved protocol in compliance with Animal Welfare Act regulations and the Guide for the Care and Use of Laboratory Animals. To determine pharmacokinetic properties, non-randomized mice (n 5 3; naive male Balb/C; 7-9 weeks old; 23-25 g) were dosed with KDU691 (HCl salt; formulated in 75% polyethylene glycol 300 (PEG300) and 25% of dextrose (5 mg ml 21 ) in distilled water (D5W)). Sample size and analysis protocol followed a standardized protocol 36 . The causal prophylaxis model was carried out in two independent experiments with non-randomized mice (n 5 4 per experimental group; female CD1; 7-9 weeks old; 25-32 g) inoculated with 1 3 10 5 P. berghei sporozoites (intravenous) and orally administered 7.5 mg kg 21 KDU691 (suspension formulation of 0.5% (w/v) methylcellulose and 0.5% (v/v) Tween 80). Sample size was determined by a power analysis using binary outcome data (infected or cured mice), and showed that the use of four mice per experimental group had 90% power to detect a difference of 75% (for example, three mice). The timing of drug administration occurred immediately after parasite inoculation (day 0), 24 h after inoculation (day 1), 36 h after inoculation, or 48 h after inoculation (day 2). Parasitaemia was monitored by two methods. The In vivo Imaging System (IVIS 100, Xenogen; Calipar Life Science) was used to acquire the bioluminescence signal (5-min acquisitions) as previously described 29 were fed with this blood as described previously 37 . P. cynomolgi liver assay: sporozoite infection of primary rhesus hepatocytes. Rhesus monkey hepatocytes were isolated from liver lobes as described by previously 38 . Sporozoite infections were performed within 3 days after hepatocyte isolation. Sporozoite inoculation of primary Rhesus hepatocytes was performed as described previously 5, 39 . On day 6, intracellular P. cynomolgi malaria parasites were fixed, stained with purified rabbit antiserum reactive against P. cynomolgi Hsp70.1 (ref. 5) , and visualized with FITC-labelled goat anti-rabbit IgG antibodies. Quantification of small 'hypnozoite' exoerythrocytic forms (1 nucleus, a small round shape, maximally 7 mm in diameter) or large 'developing parasite' exoerythrocytic forms (more than 1 nucleus, larger than 7 mm and round or irregular shape) was determined for each well using a high-content imaging system (Operetta, Perkin-Elmer). P. falciparum asexual blood-stage culture and assay. P. falciparum isolates were maintained by standard methods 40 in an atmosphere of 93% N 2 , 4% CO 2 , 3% O 2 at 37 uC in complete culturing medium (10.4 g l 21 RPMI 1640 (without phenol red, with 2.1 mM glutamine), 5.94 g l 21 HEPES, 5 g l 21 albumax II, 50 mg l 21 hypoxanthine, 2.1 g l 21 sodium bicarbonate, 10% human serum and 43 mg l 21 gentamicin). Human erythrocytes served as host cells. In vitro antimalarial activity was measured using a modified SYBR Green cell proliferation assay 4 . In vivo mouse therapeutic efficacy assay. All in vivo efficacy studies were approved by the veterinary authorities of the Canton Basel-Stadt. In vivo antimalarial activity was assessed in non-randomized, non-blinded mice (n 5 3 (once daily regimen) or n 5 5 (twice daily regimen) per experimental group; female NMRI; 6 weeks old; 20-22 g) intravenously infected on day 0 with 2 3 10 7 erythrocytes infected with P. berghei GFP parasites (PbGFPCON, donated by A. P. Waters and C. J. Janse) 40 . Power analysis using a binary outcome data (infected or cured mice) showed that the use of three mice had .80% power to detect a difference of 67% (for example, two mice), whereas the power increased to .90% to detect a difference of 40% (for example, two mice) when the sample size increased to five. Compounds formulated in 0.5% methylcellulose/0.5% Tween 80 were administered orally in a volume of 10 ml kg 21 as a single dose (24 h after infection), or as four consecutive doses (6, 24, 48 and 72 h after infection). With the single-dose regimen at 96 h after infection, parasitaemia was measured using standard flow cytometry techniques or standard microscopy 41 . Activity was calculated as the difference between the mean percentage parasitaemia for the control and treated groups, expressed as a percentage of the control group. The survival time in days was also recorded up to 30 days after infection, at which time parasite-free animals were considered cured. Ex vivo schizont assay of P. falciparum and P. vivax isolates. Clinical isolates of P. vivax and P. falciparum (eight samples each) were collected from the Mae Sot region of Tak Province (Thailand) in 2011. All samples were collected from patients with acute malaria (with a mono species parasitaemia of 5,000-8,000 parasites per microlitre, .80% of the parasites at ring stage and no antimalarials or antibiotics taken by the patient in the past 30 days) attending the clinics of Shoklo Malaria Research Unit. After obtaining written consent, the sensitivity of the parasite isolates was tested, as previously described 30, 31 . The clinical samples were collected and tested in accordance to protocols approved by The Center for Clinical Vaccinology and Tropical Medicine at University of Oxford (OXTREC 58-09), which had been ratified by the Ethics Committee of the Faculty of Tropical Medicine at Mahidol University.
Gametocyte viability assay. P. falciparum NF54 stage III2V gametocytes were isolated by discontinuous Percoll gradient centrifugation of parasite cultures treated with 50 mM N-acetyl-D-glucosamine for 3 days to kill asexual parasites. Gametocytes were seeded in 96-well plates, and viability was measured by a modified Plasmodium lactate dehydrogenase assay using resazurin as a substrate following a 72-h compound exposure 32 . Compounds were tested in a 9-point dose response series (0.1 nM-1 mM in 0.5 log 10 dilutions) in quadruplicate (two different plates with two different parasite batches). Controls MIN (1 mM DHA), MAX (vehicle) and full dose response of reference compound (DHA) were run in a standardized plate format. Data were expressed as the percentage effect relative to the MIN and MAX wells of the assay plate. Data were analysed with GraphPad Prism 5 and IC 50 values were calculated by applying a four-parameter nonlinear regression model. Gametogenesis assay. Cultures containing P. falciparum NF54 mature (stage V) gametocytes were pre-incubated with compound for 24 h. KDU691 was tested at 0.2 mM (1 3 IC 50 ) and 20 mM (100 3 IC 50 ), and controls included 0.1% DMSO (vehicle) and 1 mM DHA. Subsequently, gametogenesis was induced by adding xanthurenic acid to a final concentration of 50 mM. An additional control included a sample treated with 0.02% (w/v) NaN 3 to block gametogenesis (sample t 5 0 h). Parasites were incubated for 8 h at 20 uC, and emerged gametes were immunostained with an Alexa-Fluor-488-labelled anti-Pfs25 antibody as previously described 33 . Gametes were quantified by flow cytometry, and data were expressed as the fraction of Pfs25-positive cells in the population of uninfected and infected RBCs. Standard membrane feeding assay. Cultures containing mature (stage V) P. falciparum NF54 gametocytes were pre-incubated with compound for 24 h. Cells were spun down (10,000g, 20 s) and resuspended in human serum and RBCs to a final haematocrit of 50%. Fresh compound was added and the blood meal was fed to A. stephensi mosquitoes. Seven days after the blood meal, the number of midgut oocysts was determined by microscopy 34 . Compounds were tested in a 9-point dose response series (0.1 nM-1 mM in 0.5 log 10 dilutions) in duplicate. Controls included two vehicle controls (0.1% DMSO) and two positive controls (1 mM DHA). Per sample, a total of 20 mosquitoes were dissected to determine oocysts loads. Representative data are shown from one of two independent experiments and expressed as the percentage effect relative to vehicle control, and analysed with the GraphPad Prism 5 software package by applying a four-parameter nonlinear regression model. Parasite synchronization. In brief, a Dd2 culture was treated consecutively with 5% sorbitol (6-h spacing), and 36 h after the first sorbitol treatment, the cultures were captured on MACS LD columns (Miltenyi Biotec). Purified schizonts were eluted with complete culturing media and combined into a fresh culture. The flask
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was incubated at 37 uC with gentle shaking (110 r.p.m.) for 2.5 h to promote optimal reinvasion. After this incubation, the culture was filtered over a fresh MACS LD column to re-capture any remaining schizonts, and to allow the uninfected and newly parasitized RBCs with ring-stage parasites to flow through. The entirety of reinvasion occurred over a 3-h period, so the midpoint was used to establish t 5 0 h in the parasite life cycle. Onset of inhibition studies. A synchronized culture was divided into 100 ml volumes (,2% parasitaemia in 2.5% haematocrit) within a 96-well tissue culture plate (BD Biosciences). Stage of action studies were carried out by immediately adding 3 3 IC 50 inhibitor and parasites were visualized at t 5 24, 32, 40, 48 and 60 h after synchronization. Giemsa-stained parasites were visualized (.1,000 cells per sample) and recorded by a light microscope (Carl Zeiss Axiostar Plus microscope, 1003 objective lens) equipped with a PowerShot G6 digital camera (Canon).
To test the effect of KAI407 exposure duration on parasite maturation throughout a single (,48 h) asexual blood-stage cycle, 125 nM KAI407 was added either immediately after synchronization or every 2 h starting at life cycle t 5 34 h (trophozoite stage). Alternatively, 125 nM KAI407 was present in the media immediately after synchronization, and then washed out (3 3 1 ml culturing medium, then resuspended to the original volume) at these same time points. In both experiments, the parasitaemia of ring-stage parasites was determined by microscopy 60 h after final synchronization. Drug-treated wells were compared to a DMSO-treated control to determine the percentage inhibition. Physical disruption/merozoite release assay. Synchronized parasites were cultured to schizogony (t 5 42 h) and then treated with DMSO, 1 mM E-64, or ,5 3 IC 50 drug: 125 nM KAI407, 15 nM KAI715 or 150 nM KDU691. At t 5 51 h, parasites were sheared by 20 strokes through a 28.5-gauge needle as previously described 10 .
The cultures were incubated for a further 8 h, and ring-stage parasitaemias determined by microscopy (.1,000 cells counted per sample).
Imaging of drug-treated PfATP4-GFP. Generation of the PfATP4-GFP line and subsequent fluorescence imaging was as previously described 12 . The drugarrested phenotype induced by KAI407 treatment of this line was investigated with sorbitol synchronized populations. Either 500 nM KAI407 or DMSO (control) was added to early schizonts (t 5 40 h) and incubated for 4 h. Cells were then immediately fixed with paraformaldehyde and glutaraldehyde for imaging. Images are representative of two biological replicates.
In vitro resistance selection and microarray analysis. A clonal population of P. falciparum Dd2 parasites was used to initiate two or three independent parasite cultures under the initial selection pressure of 12 nM KAI407, 1 nM KAI715 or 40 nM BQR695. Stepwise drug evolution continued until the final concentration was at least threefold higher than the initial concentration (typically 802120 days). For each of the ten resistant strains, CNVs and SNVs were detected using a wholegenome tiling array and analysed with PfGenominator (freely available at http:// winzeler.ucsd.edu/software.html) 13 . The susceptibility of each resistant strain to KAI407, KAI715, KDU691 and BQR695 was determined by the 72-h SYBR Green cell proliferation assay 4 , with four independent experiments assayed in duplicate. PI(4)K variation in a transgenic P. berghei line. Introduction of the PI(4)Kresistance-conferring mutation PbPI(4)K(His1477Tyr) (equivalent to His1484Tyr in PfPI(4)K) into a transgenic P. berghei ANKA line expressing luciferase (PbANKA; obtained from MR4, MRA-868) was generated using an established protocol 35 . In brief, an 1,857-bp fragment of PbPI(4)K (PBANKA_110940) was PCR-amplified using primer pair p1/p2 ( Supplementary Table 1 ) and cloned into a Topo TA vector (Invitrogen). Sequence fidelity was verified using primers p5 to p9. Subsequently, site-directed mutagenesis (Stratagene) was performed with primers p3/p4 to introduce the non-synonymous coding mutation C4519T (encodes Tyr 1477; mutation located 556 bp upstream of the stop codon). The KpnI/PspM01-digested fragment was cloned into pl0001-TgDHFR-KO (obtained from MR4, MRA-770), in which the pycrt 39 untranslated region (UTR) (terminating sequence; primers p12/p13) and PbPI(4)K 39 UTR (second homology site; primers p10/p11) were also included. In parallel, a second plasmid was constructed with the native pbpi4k gene fragment to serve as recombinant control. After transfection, recombinant PbANKA parasites were selected in vivo with non-randomized mice (female Swiss Webster mice, 6 weeks old, ,25 g), and drinking water was supplemented with pyrimethamine. Animal protocols were approved and performed in accordance with rules and regulations of Institution Animal Care and Use Committee (IACUC) of Columbia University. Presence of transfected parasites was verified with direct sequencing using primers p14 to p20. Clonal parasite lines were isolated by in vivo limiting dilution, and the PI(4)K variation verified by direct sequencing. All primers for this study are listed in Supplementary Table 1 . Drug activity was measured in three independent experiments performed in quadruplicate using the in vitro P. yoelii liver schizont assay. ZFN engineering. ZFNs targeting the genomic region encoding the kinase domain of pfpi4k (PF3D7_0509900) were designed by Sigma-Aldrich, and a ZFN pair recognizing the sequence (59-CTGACAGTCGATGTGGTAAAAATAAAAGGA AATA-39) at the exon-3/intron-3 boundary was selected based on activity in a yeast proxy assay 42 . The ZFN pair was subcloned into a pDC2-based expression vector downstream of a calmodulin (PF14_0323) promoter essentially as described 17 , yielding the vector pZFN PI(4)K -hDHFR. A ,1.7-kb donor template, encompassing 1,217 bp of the pfpi4k coding sequence and 466 bp of the 39 UTR, was amplified with primers p3480 and p3498 and inserted into the BstAPI and ZraI sites of pZFN PI(4)K -hDHFR to yield the editing plasmid pZFN PI(4)K -hDHFR. To prevent recleavage of an edited genome, three silent mutations were introduced by sitedirected mutagenesis into the ZFN-binding site using primers p3496 and p3497 (see Fig. 3b ). Further modifications were overlaid on this donor sequence to generate transfection plasmids bearing mutations at Ser1320Leu (pZFN-PI(4)K S1320L -hDHFR; primers p3506 and p3507), Tyr1356Phe (pZFN-PI(4)K Y1356F -hDHFR; primers p3508 and p3509), Tyr1356stop (pZFN-PI(4)K Y1356X -hDHFR; primers p3510 and p3511) and His1484Tyr (pZFN-PI(4)K H1484Y -hDHFR; primers p3512 and p3513). The ZFN primers are listed in Supplementary Table 1 . A clonal Dd2 line was transfected with the pZFN-PI(4)K-hDHFR editing plasmids, and selected with 2.5 nM WR99210 the day after electroporation. On day 6 after electroporation, WR99210 pressure was removed, and parasites were observed microscopically at day 14. Clonal parasites were obtained by limiting dilution, and successful editing was determined by direct sequencing. The susceptibility of each edited line to KAI407, KAI715, KDU691 and BQR695 was determined by three independent experiments performed in triplicate using the 72-h SYBR Green cell proliferation assay 4 . Whole-genome sequencing analysis. Genomic DNA libraries were prepared for whole-genome sequencing using the Illumina NexTera protocol of simultaneous fragmentation and adaptor ligation and indexed using the TruSeq Dual Index Sequencing primers (v. 2013, Illumina.). DNA libraries were clustered and run on an Illumina HiSeq 2000, according to manufacturer's instructions. An internally developed whole-genome sequencing pipeline, named PlaTypUS (M. Manary et al., manuscript submitted), was used to align and analyse all whole-genome sequencing data. The program integrates many community-developed tools into its processing pipeline. To generate alignments, PlaTypUS follows a multi-step alignment process to execute quality control measures on an alignment map. FASTQ files obtained from sequencing were aligned to the Pf3D7 reference (PlasmoDB v9.1) for SNV and CNV analysis. Expression of GFP-tagged PfPI(4)K and PfRab11A. The full-length pfpi4k and pfrab11a genes were PCR amplified from genomic DNA using primers p3727/p3772 and p3730/p3731, respectively, and inserted into a pDC2-based vector behind GFP to generate the expression plasmids pDC2-PbEF1alphapro-GFP-PfPI(4)K-attP-BSD and pDC2-PbEF1alphapro-GFP-PfRab11A-attP-BSD. The Asp139Tyr mutation was introduced by site-directed mutagenesis into the pfrab11a coding sequence using primers p3736/p3737, yielding the plasmid pDC2-PbEF1alphapro-GFP-PfRab11A-D139Y-attP-BSD. The expression plasmids were then transfected into the Dd2-attB parasite line using attP 3 attB integrase-mediated recombination 18 . Drug activity against each transgenic line was determined by three independent experiments performed in duplicate using the 72-h SYBR Green cell proliferation assay 4 . Human lipid kinase panel. The biochemical inhibitory activities of human lipid kinases were measured with either Kinase-Glo (Promega) for PI(4)KIIIb and the a and b isoforms of phosphatidylinositol-3-OH kinase (PI(3)K), or Adapta (Invitrogen) for the d and c isoforms of PI(3)K. A detailed description of the Kinase-Glo assays is available from ref. 43 . The Adapta assays were run as follows: 50 nl of compound dilutions were dispensed into white 384-well low-volume polystyrene plates (Greiner). Then, 5 ml of purified recombinant PI(3)K and lipid substrate (phosphatidylinositol, or phosphatidylinositol-4,5-bisphosphate plus phosphatidylserine) were dispensed and followed by a subsequent dispense of 5 ml ATP (final assay volume 10 ml). The enzymatic reaction was incubated at room temperature. The standard reaction buffer for the Adapta TR-FRET assay contained 10 mM Tris-HCl, pH 7.5, 3 mM MgCl 2 , 50 mM NaCl, 1 mM dithiothreitol (DTT) and 0.05% CHAPS (v/v). Reactions were stopped with 5 ml of a mixture of EDTA containing the Eu 31 -labelled anti-ADP antibody and the Alexa-Fluor-647-labelled ADP tracer in a proprietary TR-FRET dilution buffer. Plates were read 15-60 min later in a Synergy2 reader using an integration time of 0.4 s and a delay of 0.05 s. Controls for 100% inhibition of the kinase reaction were performed by replacing PI(3)K with the equivalent volume of the standard reaction buffer. The controls for the 0% inhibition were performed with the solvent vehicle of the compounds (90% DMSO in H 2 O (v/v)). A reference compound was included in all assay plates and each compound was assayed in a 16-point, 1:3 dilution series. Human protein kinase panel. The human protein kinase selectivity profile for KAI407 and KDU691 was carried out against a panel of 40 recombinant kinases. Inhibition of kinase-dependent substrate phosphorylation was measured by the Caliper mobility shift assay technology using microfluidic capillary electrophoresis as previously described 44 .
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Homology modelling. The P. falciparum PI(4)K model was built by homology modelling using the X-ray crystallographic coordinates for human PI(3)Kc in complex with an inhibitor (Protein Data Bank (PDB) accession 3ENE) as a template. The kinase domain of PfPI(4)K (amino acid boundaries: N1261-M1559) were aligned to that of PI(3)Kc (kinase domain: A557-A1102). Fully flexible ligand docking was performed with Glide (version 5.5; Schrödinger). The PyMOL Molecular Graphics System (v.1.2r2, Schrödinger) was used to render the models and prepare figures. Cloning and expression of PvPI(4)K. The full-length coding sequence of PvPI(4)K (PVX098_050) was codon-optimized for baculovirus expression, synthesized and cloned into pFastBac-HTa (Invitrogen) in frame with the amino-terminal polyhistidine tag using the EcoRI and HindIII restriction sites. Recombinant bacmid clones were generated by site-specific transposition in E. coli DH10Bac (Invitrogen). The pFastBacHTa-PvPI(4)K plasmid was used as a template for site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The primers used for mutagenesis are listed in Supplementary Table 1 . All mutation sites, as well as absence of errors across the whole gene, were confirmed by direct DNA sequencing. The subsequent steps for bacmid isolation, transfection and selection of the recombinant viruses were performed according to the manufacturer's protocol (Bac-to-Bac system, Invitrogen).
SF9 cells, cultured in SF-900 III serum-free medium, were transfected with recombinant baculovirus at 1/200 (v/v) and incubated at 27 uC for 72 h. The pellets were collected after centrifugation and re-suspended in cell lysis buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5% glycerol, 0.01% Triton X-100, 0.5 mM TCEP and 13 complete protease inhibitor cocktail without EDTA (Roche Diagnostics)). The cell suspension was lysed by sonication and the clarified supernatant was loaded onto a 1 ml HisTrap affinity column (GE Healthcare) pre-equilibrated with buffer A (20 mM Tris, pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP, 20 mM imidazole and 13 complete protease inhibitor cocktail without EDTA). The protein was eluted with buffer B (buffer A with 300 mM imidazole), and fractions containing PvPI(4)K were pooled and purified by a gel-filtration column (Hi-Load 16/60 Superdex 200, GE Healthcare) equilibrated with 20 mM Tris, pH 7.5, 5% glycerol, 500 mM NaCl, 5 mM DTT and 13 protease inhibitor cocktail without EDTA. Protein concentrations were determined by the calculated protein extinction coefficient (e 280 nm 5 12,5875 M 21 cm 21 ). Aliquots were flash frozen in liquid nitrogen and immediately stored at 280 uC. All PvPI(4)K constructs were purified with this same protocol. PI(4)K enzymatic assay. L-a-phosphatidylinositol (Avanti Polar Lipid), dissolved in 3% n-octylglucoside (Roche Diagnostics), was used as the lipid substrate for the PI(4)K activity assay. PvPI(4)K was assayed using Transcreener ADP 2 FP detection kit (BellBrook) in a black, solid 384-well plate (Corning). The final assay volume was 10 ml and contained 1 nM of the respective PvPI(4)K construct in 10 mM Tris, pH 7.5, 1 mM DTT, 10 mM ATP, 5 mM Mn 21 , 0.2% Triton X-100 and 11 mM phosphatidylinositol/octylglucoside. The enzyme reaction was performed for 1 h at room temperature and was stopped by adding 10 ml of detection mix containing 13 stop buffer, 4 nM AMP Alexa Fluor 633 tracer, and 20 mg ml 21 ADP antibody. Fluorescence polarization measurements were performed on the Infinite M1000 plate reader (Tecan) with l ex 5 635 nm and l em 5 680 nm (20-nm bandwidth). IC 50 values were calculated from three independent experiments performed in triplicate using Graphpad Prism software. In vivo detection of PI(4)P pools. To detect PI(4)P within the parasite, the PH domain of yeast Osh2 was amplified from pREP41 (refs 21, 45) (provided by M. Ellis and F. Chang) using primers p2987b/p2988. The Osh2 PH domain was inserted as a dimer behind GFP to generate the expression vector pDC2-PbEF1alphapro-GFP-PH Osh2 -attP-BSD, and transfected into the Dd2-attB parasite line using Extended Data Figure 2 | Imidazopyrazine and quinoxaline compounds arrest parasites in late schizogony before completion of daughter cell formation. a, The onset of action for KAI407 was investigated using a highly synchronized population of blood-stage parasites. Complete culture medium containing 125 nM KAI407 was replaced with drug-free medium at the time indicated in 2-h intervals. The resultant parasitaemia in the next life cycle (t 5 72 h) was normalized to untreated parasites (mean 6 s.d.; n 5 4). The time course represents trophozoite-stage parasites (t 5 34 h) through the maturation of schizonts (t 5 48 h). b, c, The plasma membrane marker PfATP4-GFP was used to visualize plasma membrane ingression around developing daughter merozoites, with nuclei stained by Hoechst 33342. Parasites treated with DMSO (control) formed clearly defined daughter cells uniformly surrounded by the plasma membrane. Conversely, parasites treated with 500 nM KAI407 for 4 h (KAI407-treated) had a disorganized membrane structure. Representative images from a single experimental replicate are shown (n 5 2). Scale bar, 5 mm. d, Microscopy of Giemsa-stained parasites treated with ,5 3 IC 50 drug (125 nM KAI407, 15 nM KAI715, 150 nM KDU691 or 400 nM BQR695) or DMSO vehicle. Representative images from a single experimental replicate are shown (n 5 3). e, Measurement of merozoite viability via the merozoite release assay. The ability of merozoites to reinvade fresh RBCs after mechanical rupture of drug-arrested schizonts treated with 125 nM KAI407, 15 nM KAI715, 150 nM KDU691 or 400 nM BQR695 was compared to parasite reinvasion of untreated (DMSO) parasites. E-64 (grey), a known inhibitor of merozoite egress, was used as a control at 1 mM (mean 6 s.d.; n 5 4).
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